PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 3, 20260 citationsOpen Access

Design, synthesis, anticancer activity, and mechanistic investigation of 4,5,6,7-tetrahydrobenzo b thiophene carboxamides as CDK-2 inhibitors: in vitro and in silico DFT and molecular docking study

View Full Paper
KAKurls E. AnwerRRRamadan M. RamadanENEman S. Nossier

Key Points

  • This research aims to design and evaluate 4,5,6,7-tetrahydrobenzo[b]thiophene carboxamides as potential CDK-2 inhibitors with anticancer properties.
  • Synthesized 4,5,6,7-tetrahydrobenzo[b]thiophene carboxamides using conventional heating and microwave-assisted techniques.
  • Assessed anticancer effects against HepG-2, MCF-7, and MDA-MB-231 carcinoma cell lines.
  • Conducted molecular docking to study binding interactions with cDK-2 receptor.
  • Compound 11 showed the highest cDK-2 inhibition, nearly threefold greater than roscovitine.
  • Significant cytotoxicity against HepG-2, MCF-7, and MDA-MB-231 cell lines observed with specific analogues.
  • MDA-MB-231 cell cycle was arrested at the G0/G1 phase, indicating apoptotic effects.

Abstract

Utilising drug design methodologies including bioisosteric modification and substituents variation, sets of 4,5,6,7-tetrahydrobenzobthiophene carboxamides were synthesised, by conventional heating and eco-friendly microwave-assisted techniques, as cDK-2 inhibitors. these entities were assessed for their antitumor effects against hepatic hepG-2 and breast McF-7 and MDa-MB-231 carcinomas, in which dimethoxy 5 and dimethyl-bearing analogues 6 and 11 demonstrated significant cytotoxicity and selectivity against the examined cancer cells. consequently, they were chosen for further assays to determine their mechanism. the findings suggest that these compounds may exert cytotoxicity by inhibiting cDK-2. compound 11 displayed the highest cDK-2 inhibition, exceeding roscovitine by nearly threefold. Besides, it arrested the MDa-MB-231 cell cycle at the G0/G1 phase by apoptotic stimulation. Molecular modelling showed strong binding of the bioactive analogues to the active pocket of cDK-2 receptor, suggesting their potential as lead inhibitors.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Anwer et al. (2026) studied this question.

synapsesocial.com/papers/6a1fc56bdee9eb8c0dce6d8fhttps://doi.org/10.5445/ir/1000193699
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Design, synthesis, anticancer activity, and mechanistic investigation of 4,5,6,7-tetrahydrobenzo[ b ]thiophene carboxamides as CDK-2 inhibitors: in vitro and in silico DFT and molecular docking study2026 · 1 citations
  2. 2Integrated DFT, molecular docking, and molecular dynamics investigation of some novel 2-thiohydantoin analogues as potent CDK2 inhibitors for anticancer therapy2026 · 8 citations
  3. 3Synthesis, biological profile and computational insights of new derivatives of benzo [B][1,4] diazepines as prospective anticancer agents for inhibiting the CDK-2 protein2024 · 9 citations
  4. 4Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors2024 · 2 citations
  5. 5Design and Synthesis of Novel Series of Thiophene-2, 5-dicarbohydrazide Derivatives as Potential Anticancer Agents2024 · 2 citations